Loading...

We've got a brand new version of Simply Wall St! Try it out

Sunniva

CNSX:SNN
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SNN
CNSX
CA$64M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Sunniva Inc., a vertically integrated cannabis company, focuses on the cultivation, production, and distribution of various therapeutic solutions in Canada and the United States. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • Sunniva has significant price volatility in the past 3 months.
SNN Share Price and Events
7 Day Returns
-12.1%
CNSX:SNN
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-73.3%
CNSX:SNN
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
SNN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sunniva (SNN) -12.1% 40.7% -45.9% -73.3% - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • SNN underperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • SNN underperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Sunniva undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sunniva. This is due to cash flow or dividend data being unavailable. The share price is CA$1.52.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sunniva's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sunniva's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:SNN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-1.00
CNSX:SNN Share Price ** CNSX (2019-09-19) in CAD CA$1.52
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sunniva.

CNSX:SNN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:SNN Share Price ÷ EPS (both in CAD)

= 1.52 ÷ -1.00

-1.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sunniva is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Sunniva is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Sunniva's expected growth come at a high price?
Raw Data
CNSX:SNN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sunniva, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sunniva's assets?
Raw Data
CNSX:SNN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$1.87
CNSX:SNN Share Price * CNSX (2019-09-19) in CAD CA$1.52
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:SNN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:SNN Share Price ÷ Book Value per Share (both in CAD)

= 1.52 ÷ 1.87

0.81x

* Primary Listing of Sunniva.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sunniva is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Sunniva's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Sunniva has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sunniva expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sunniva has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sunniva expected to grow at an attractive rate?
  • Unable to compare Sunniva's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sunniva's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Sunniva's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:SNN Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:SNN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:SNN Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
CNSX:SNN Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 29 -25 -36
2019-03-31 28 -28 -26
2018-12-31 19 -16 -29
2018-09-30 19 -10 -18
2018-06-30 20 -9 -17
2018-03-31 19 -5 -23
2017-12-31 16 -5 -18
2017-09-30 10 -4 -19
2017-06-30 6 -4 -14
2017-03-31 2 -4 -6
2016-12-31 0 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sunniva is high growth as no earnings estimate data is available.
  • Unable to determine if Sunniva is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:SNN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sunniva Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:SNN Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
CNSX:SNN Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -1.00
2019-03-31 -0.76
2018-12-31 -0.91
2018-09-30 -0.64
2018-06-30 -0.61
2018-03-31 -0.86
2017-12-31 -0.70
2017-09-30 -0.87
2017-06-30 -0.74
2017-03-31 -0.32
2016-12-31 -0.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sunniva will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of SNN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Sunniva's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Sunniva's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sunniva's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sunniva has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sunniva performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sunniva's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sunniva does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sunniva's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sunniva's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Sunniva's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sunniva Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:SNN Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 28.70 -36.30 36.76
2019-03-31 27.81 -26.24 32.34
2018-12-31 18.79 -29.05 33.00
2018-09-30 19.23 -18.48 28.46 0.11
2018-06-30 20.05 -16.99 28.14 0.11
2018-03-31 18.86 -22.82 24.27 0.11
2017-12-31 16.07 -17.51 18.26 0.11
2017-09-30 10.25 -19.36 14.00 0.31
2017-06-30 5.69 -14.02 6.41 0.31
2017-03-31 2.41 -5.56 4.35 0.31
2016-12-31 0.04 -6.89 3.60 0.31
2015-12-31 -1.91 1.34 0.51
2014-12-31 -2.97 1.84 1.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sunniva has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sunniva has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sunniva improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sunniva's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sunniva has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sunniva's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sunniva's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sunniva is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sunniva's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Sunniva's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sunniva Company Filings, last reported 2 months ago.

CNSX:SNN Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 73.02 29.08 1.60
2019-03-31 87.91 27.83 2.14
2018-12-31 85.01 11.81 2.14
2018-09-30 63.34 12.36 3.55
2018-06-30 67.10 12.23 17.53
2018-03-31 63.43 9.16 29.56
2017-12-31 34.30 18.76 11.42
2017-09-30 29.62 17.21 0.71
2017-06-30 31.04 19.46 4.30
2017-03-31 14.25 9.67 9.61
2016-12-31 14.25 9.67 9.61
2015-12-31 -0.76 1.55 0.04
2014-12-31
  • Sunniva's level of debt (39.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Sunniva's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sunniva has less than a year of cash runway based on current free cash flow.
  • Sunniva has less than a year of cash runway if free cash flow continues to grow at historical rates of 82.5% each year.
X
Financial health checks
We assess Sunniva's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sunniva has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sunniva's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sunniva dividends.
If you bought CA$2,000 of Sunniva shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sunniva's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sunniva's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:SNN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:SNN Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sunniva has not reported any payouts.
  • Unable to verify if Sunniva's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sunniva's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sunniva has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sunniva's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sunniva afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sunniva has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sunniva's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tony Holler
COMPENSATION CA$340,626
AGE 67
CEO Bio

Dr. Anthony F. Holler, also known as Tony, M.D. is a Co-founder, Chairman of the Board and Chief Executive Officer of Sunniva Inc. Dr. Holler has been the Independent Chairman of CRH Medical Corporation since December 21, 2005. Dr. Holler served as Treasurer at Response Biomedical Corp. until January 12, 2017 and served as its Interim Chief Executive Officer from September 16, 2014 until May 20, 2015. Dr. Holler served as the Chief Executive Officer and President at Inviro Medical. He previously served as the Chief Financial Officer at Response Biomedical Corp. Dr. Holler served as Chairman and Interim Chief Executive Officer of Inviro Medical Devices Limited. Dr. Holler served as Chief Executive Officer at ID Biomedical Corporation from March 27, 2001 to December 2005 and also served as its President. He has been Chairman of Trevali Resources Corp. since October 2010. He served as Non-Executive Chairman of Q2 Gold Resources Inc. and its Director since June 18, 2007. He was Chairman of Inviro Medical since August 2006. He served as the Chairman of Trevali Mining Corporation from October 2010 to February 14, 2014. Dr. Holler served as Non-Executive Chairman of Corriente Resources Inc. from 2003 to June 2010. He served as Vice-Chairman of Response Biomedical Corp. since November 2015 until November 29, 2016. He serves as a Member of Advisory Board of Roadmap Capital Inc. Dr. Holler has been an Independent Director of CRH Medical Corporation since December 21, 2005. He served as a Director of Inviro Medical since April 27, 2006. He served as a Director of Response Biomedical Corp. since March 30, 2006 until November 29, 2016. He served as a Director of Neptune Technologies & Bioressources, Inc. since July 5, 2011 and Corriente Resources Inc. since September 10, 2003. He served as a Director of Vaxent. Dr. Holler has been a Director of Sunniva Inc. since August 11, 2014. Dr. Holler served as a Director of ID Biomedical Corporation since March 04, 1991. He served as an Emergency physician at University Hospital at University of British Columbia. Dr. Holler is a Member of the British Columbia College of Physicians and Surgeons. He holds a Bachelor of Science in 1975 and a Medical Degree in 1979 from the University of British Columbia.

CEO Compensation
  • Tony's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Tony's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Sunniva management team in years:

0.3
Average Tenure
55
Average Age
  • The average tenure for the Sunniva management team is less than 2 years, this suggests a new team.
Management Team

Tony Holler

TITLE
Co-founder
COMPENSATION
CA$341K
AGE
67

Duncan Gordon

TITLE
Chief Operating Officer
COMPENSATION
CA$251K
AGE
55
TENURE
2.8 yrs

David Negus

TITLE
Consultant
COMPENSATION
CA$2M
AGE
51
TENURE
0.3 yrs

Mark Kimmins

TITLE
President of NHS
COMPENSATION
CA$5M
AGE
52
TENURE
0.8 yrs

Kevin Wilkerson

TITLE
President
AGE
59
TENURE
0.2 yrs

David Lyle

TITLE
Chief Financial Officer
AGE
55
TENURE
0.3 yrs

Rob Knowles

TITLE
Vice President of Corporate Development

Jose Calderon

TITLE
Head of Grower
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Sunniva board of directors in years:

2.2
Average Tenure
65.5
Average Age
  • The average tenure for the Sunniva board of directors is less than 3 years, this suggests a new board.
Board of Directors

Tony Holler

TITLE
Co-founder
COMPENSATION
CA$341K
AGE
67

Ian Webb

TITLE
Director
COMPENSATION
CA$222K
AGE
68
TENURE
5.1 yrs

Norm Mayr

TITLE
Director
COMPENSATION
CA$230K
AGE
64
TENURE
2.2 yrs

Todd Patrick

TITLE
Lead Director
COMPENSATION
CA$2M
AGE
56
TENURE
2.2 yrs

Michael Barker

TITLE
Director
COMPENSATION
CA$192K
AGE
74
TENURE
2.2 yrs

Luke Stanton

TITLE
Director
COMPENSATION
CA$192K
AGE
38
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • Sunniva individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
10. Jul 19 Sell Leith Pedersen Individual 04. Jun 19 10. Jul 19 -792,100 CA$3.68 CA$-2,257,593
09. Jan 19 Buy Mark Kimmins Individual 18. Dec 18 18. Dec 18 1,000 CA$2.41 CA$2,374
28. Dec 18 Buy Kevin Wilkerson Individual 28. Dec 18 28. Dec 18 478,983 CA$3.71 CA$1,777,027
X
Management checks
We assess Sunniva's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sunniva has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Can We See Significant Insider Ownership On The Sunniva Inc. (CNSX:SNN) Share Register?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Sunniva is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Are Sunniva Inc's (CNSX:SNN) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like Sunniva Inc (CNSX:SNN), with a market cap of CA$180m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Should You Be Concerned About Sunniva Inc's (CNSX:SNN) Investors?

I am going to take a deep dive into Sunniva Inc’s (CNSX:SNN) most recent ownership structure, not a frequent subject of discussion among individual investors. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … CNSX:SNN Ownership Summary August 21st 18

Simply Wall St -

How Financially Strong Is Sunniva Inc (CNSX:SNN)?

Sunniva Inc (CNSX:SNN) is a small-cap stock with a market capitalization of CA$251.58m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Companies operating in the Pharmaceuticals industry,

Simply Wall St -

Company Info

Description

Sunniva Inc., a vertically integrated cannabis company, focuses on the cultivation, production, and distribution of various therapeutic solutions in Canada and the United States. The company operates through Patient Counselling, Merchandising, and Cultivation & Extraction segments. It offers its products under the Sun Fire, Kyndness, and Herbella brands. The company was formerly known as Sunniva Holdings Corp. and changed its name to Sunniva Inc. in August 2017. Sunniva Inc. was founded in 2014 and is headquartered in Vancouver, Canada.

Details
Name: Sunniva Inc.
SNN
Exchange: CNSX
Founded: 2014
CA$64,093,136
42,166,537
Website: http://www.sunniva.com
Address: Sunniva Inc.
1200-200 Burrard Street,
Vancouver,
British Columbia, V7X 1T2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX SNN Common Shares Canadian National Stock Exchange CA CAD 10. Jan 2018
OTCPK SNNV.F Common Shares Pink Sheets LLC US USD 10. Jan 2018
Number of employees
Current staff
Staff numbers
119
Sunniva employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:24
End of day share price update: 2019/09/19 00:00
Last estimates confirmation: 2019/04/29
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.